Hangil Park

Hangil Park has worked in the biotechnology industry since 2001. Hangil began their career as a Scientist at eXegenics in 2001, followed by a Scientist role at MacroGenics in 2002. In 2005, they joined Galaxy Biotech as a Senior Scientist and Staff Scientist, where they were involved in target identification of various human tumors, antibody cloning/humanization, and antibody engineering. In 2016, they moved to FivePrime Therapeutics as a Senior Scientist in Antibody Engineering & Technologies, where they worked on antibody discovery from single B cells & hybridoma and antibody discovery for multiple IO targets. In 2019, they joined Walking Fish Therapeutics as a Director, and in 2021 they were promoted to Executive Director and Senior Director at Walking Fish Therapeutics, Inc.

Hangil Park obtained a Ph.D. in Biochemistry & Molecular Biology from Stony Brook University between 1990 and 1995. Prior to that, they earned a BS/MS in Biology (with a minor in Chemistry) from Sogang University between 1980 and 1986.